Palinavir

This classification denotes a protease inhibitor with the molecular formula C41H52N6O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 632S1WU9Z2, chemically known as 2-quinolinecarboxamide, n-(1-(((3-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(4-pyridinylmethoxy)-1-piperidinyl)-2-hydroxy-1-(phenylmethyl)propyl)amino)carbonyl)-2-methylpropyl)-, (2s-(1(1r*(r*),2s*),2alpha,4alpha))- but generally known as palinavir, which bears US NIH Compound Identifier 72981. European Medicines Agency schedules Palinavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09589MIG. The term PALINAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). PALINAVIR is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule palinavir under HS 29334910 and SITC 51575. As of Q4 2014, PALINAVIR remains the US FDA Preferred Term for this commodity. Palinavir bears US NLM identifiers UMLS ID C0663725 and NCI Concept Code C66292. SMILES: O(C1CC(N(CC1)CC(O)C(NC(=O)C(NC(=O)C1NC2C(CC1)CCCC2)C(C)C)CC1CCCCC1)C(=O)NC(C)(C)C)CC1CCNCC1.